AstraZeneca (AZN) admits 45,750 new employee scheme shares to LSE

Rhea-AI Filing Summary

AstraZeneca PLC has admitted 45,750 new ordinary shares of $0.25 each to trading on the London Stock Exchange’s Main Market. These shares were issued between 20 January 2026 and 19 March 2026 under the company’s existing block admission.

The new shares arise from AstraZeneca’s employee share schemes, meaning they were created to satisfy staff share awards or options. Following this admission, the total number of AstraZeneca ordinary shares in issue is 1,550,980,332, all fully fungible with the existing stock.

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of March 2026 

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________

AstraZeneca PLC

INDEX TO EXHIBITS

1. Notification of Admission of Shares

20 March 2026

Notification of Admission of Further Securities to Trading (PRM 1.6.4R)

AstraZeneca PLC (the Company) announced today the following information in accordance with The Public Offers and Admissions to Trading Regulations 2024 (POATRs) PRM 1.6.4R.

1	Details of the issuer
a)	Name	AstraZeneca PLC
b)	LEI	PY6ZZQWO2IZFZC3IOL08
2	Details of the transferable securities admitted to trading
a)	Name, type and identification code	Ordinary Shares of $0.25 each ISIN: GB0009895292
b)	Regulated market	London Stock Exchange - Main Market
c)	Number of further securities issued and admitted	45,750
d)	Total number of securities in issue following admission	1,550,980,332
e)	Fungibility	Fully fungible with existing Ordinary Shares
3	Admission details
a)	Date of admission	Issued between 20 January 2026 to 19 March 2026 (admitted under a block admission dated 29 January 2021)
b)	Prospectus information	Prospectus: N/A Supplementary: N/A Company's webpage: https://www.astrazeneca.com
c)	Coverage of notification	Admission of shares under the Company's employee share schemes from 20 January 2026 up to 19 March 2026, admitted to trading on the Main Market of the London Stock Exchange under the Company's existing block admission of shares dated 29 January 2021.

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Matthew Bowden

Company Secretary

AstraZeneca PLC

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 20 March 2026

By: /s/ Matthew Bowden

Name: Matthew Bowden

Title: Company Secretary

FAQ

What did AstraZeneca (AZN) announce in this March 2026 6-K filing?

AstraZeneca announced the admission of 45,750 new ordinary shares to trading on the London Stock Exchange. These shares were issued under existing employee share schemes and increase the total share count but do not involve a separate public offering or prospectus.

How many AstraZeneca (AZN) shares are now in issue after this admission?

After this admission, AstraZeneca has 1,550,980,332 ordinary shares in issue. The 45,750 new shares were added between 20 January 2026 and 19 March 2026 under an existing block admission linked to the company’s employee share schemes.

What is the purpose of the 45,750 new AstraZeneca (AZN) shares?

The 45,750 new ordinary shares were issued to satisfy obligations under AstraZeneca’s employee share schemes. They represent shares granted or acquired by employees and are then admitted to trading on the London Stock Exchange’s Main Market under a previously established block admission.

Are the newly admitted AstraZeneca (AZN) shares different from existing shares?

The newly admitted AstraZeneca shares are fully fungible with existing ordinary shares. This means they have the same rights, characteristics, and trading status as the company’s other ordinary shares already listed on the London Stock Exchange’s Main Market.

Did AstraZeneca (AZN) use a prospectus for this share admission?

No, AstraZeneca did not use a prospectus or supplementary prospectus for this admission. The shares were admitted under an existing block admission dated 29 January 2021, with the company confirming that prospectus documentation is marked as not applicable for this transaction.

On which market are the new AstraZeneca (AZN) shares admitted to trading?

The 45,750 new ordinary shares are admitted to trading on the London Stock Exchange’s Main Market. They fall under the company’s existing block admission and are listed alongside AstraZeneca’s previously issued ordinary shares on the same regulated market.